NASDAQ · Biotechnology · USD

IN8bio, Inc. (INAB) Stock Analysis

IN8bio, Inc. (INAB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

INAB

$1.20

+$0.04 (+3.45%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INAB with… →

INAB Key Statistics

As of Sep 4, 2026

Trading

Open: $1.16
Previous Close: $1.16
Day's Range: 1.16–1.22
52-Week Range: 0.88–2.73
Volume: 22.40K
Beta: 0.29

Valuation

Market Cap: $11.83M
P/E Ratio: unprofitable
EPS (ttm): −1.34

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$19.44M
Profit margin: 0.00%
Shares Outstanding: 9.86M
1-Year Return: −44.95%

Dividend and dates

Avg Volume: 55.61K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INAB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−56.10%−47.38%−40.26%−81.38%−69.65%−48.72%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−48.72%
2025	−69.65%
2024	−81.38%
2023	−40.26%
2022	−47.38%
2021 (partial year)	−56.10%

As of September 4, 2026.

INAB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$19.44M	—
2024	$0.00	−$30.44M	—
2023	$0.00	−$30.01M	—
2022	$0.00	−$28.52M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$19.86M	−$19.44M	—
2024	$0.00	—	−$29.60M	−$30.44M	—
2023	$0.00	—	−$30.01M	−$30.01M	—
2022	$0.00	—	−$28.52M	−$28.52M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INAB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	INAB	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

IN8bio, Inc. (INAB) carries a market capitalisation of $11.83M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 18.

The most recent close on file for INAB is $1.20, dated September 4, 2026. That is +$0.04 (+3.45%) against the previous close. The 52-week range on file runs from $0.88 to $2.73. The latest close sits 36.36% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $19.44M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.34.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.3. Daily returns over the trailing 5 years annualize to a volatility of 141.01%. The trailing one-year price return is −44.95%. Measured over 5 years, that is −65.61% a year compounded.

Growth & Income

The record shows no dividend for INAB.

So far in 2026 the price is −48.72%. Across the complete calendar years on file, 2023 returned −40.26% and 2024 returned −81.38%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

IN8bio, Inc. (INAB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
IN8bio, Inc.	INAB	$11.83M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. IN8bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About IN8bio, Inc.

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Visit website →